ENTRY       D11988                      Drug
NAME        Casimersen (USAN/INN);
            Amondys 45 (TN)
PRODUCT     AMONDYS 45 (Sarepta Therapeutics)
FORMULA     C268H424N124O95P22
EXACT_MASS  7580.6386
MOL_WEIGHT  7584.4307
REMARK      ATC code: M09AX13
            Product: D11988<US>
EFFICACY    Translation inhibitor
  DISEASE   Duchenne muscular dystrophy (DMD variant amenable to exon 45 skipping) [DS:H01963]
  TYPE      Antisense oligonucleotide
COMMENT     Treatment of Duchenne muscular dystrophy
TARGET      DMD* [HSA_VAR:1756v1] [HSA:1756] [KO:K10366] (pre-mRNA exon45)
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             M MUSCULO-SKELETAL SYSTEM
              M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
               M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
                M09AX Other drugs for disorders of the musculo-skeletal system
                 M09AX13 Casimersen
                  D11988  Casimersen (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Casimersen
               D11988  Casimersen (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                DMD* [HSA_VAR:1756v1]
                 D11988  Casimersen (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11988
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11988
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D11988
DBLINKS     CAS: 1422958-19-7
///
